Estrogen - A Potential New Treatment for Women & Men with Schizophrenia

Funding Activity

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Estrogen - the major female hormone, has been shown in animal studies to decrease the two main brain chemicals (dopamine and serotonin) that are implicated in causing schizophrenia. The effect of estrogen in the brain is similar to current antipsychotic drugs. We have carried out a study that showed that when we gave 12 young women with schizophrenia 100 micrograms of estrogen in a skin patch form plus standard antipsychotic drug treament they recovered more quickly than 12 young women who received standard antipsychotic drug treatment only. 100mcg is a safe dose of estrogen. In this proposal we want to expand and clarify the pilot study resutls by conducting a 28 day trial in a total of 60 women with schizophrenia. 30 women would receive 100 mcg skin patch estrogen plus antipsychotic medication and 30 women would receive antipsychotic medicationly only. We also tested the value of adding a very small dose of oral estrogen to antipsychotic drug treatment in five men with schizophrenia and found that they made a better recovery compared to five men who received standard antipsychotic drugs only. We trialled the use of estrogen for seven days in men, but this may not have been long enough to examine the real impact of estrogen treatment in men. In this proposal we want to conduct a 14 day trial in a total of 60 men with schizophrenia. 30 men would receive 2mg of oral estrogen plus antipsychotic drug treatment and their results would be compared with 30 men who received standard antipsychotic drug treatment plus a placebo tablet identical in appearance to estrogen. For 14 days, this low dose of estrogen is very safe. Potentially estrogen may be a useful addition to the current standard treatment of schizophrenia. It may decrease the duration of acute illness and in women it may have a role in preventing relapses of schizophrenia as well as improving the general health of women with schizophrenia.

Funded Activity Details

Start Date: 01-01-2001

End Date: 01-01-2003

Funding Scheme: NHMRC Project Grants

Funding Amount: $227,545.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Psychiatry

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Antipsychotic drugs | Clinical trial | Estrogen | Men's Mental Health | Schizophrenia | Women's Mental Health